Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...
As a result Neulasta was still Amgen’s second biggest selling drug last year, with the US accounting for nearly $3.9 billion in sales, with only $609 million coming from the rest of the world.
Neulasta Global market Report 2025 : Market Size, Trends, And Global Forecast 2025-2034 Neulasta Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The neulasta ...
B12019 and Neulasta are formulations of pegfilgrastim ... Cinfa Biotech is closing in on the day it can make its biosimilar pegfilgrastim available through its license partners to more patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback